Guess which ASX 200 healthcare share just rocketed 11% on 'groundbreaking trial'

Up 67% in a year, investors are sending the ASX 200 healthcare share soaring again today.

| More on:
Shot of a young scientist using a digital tablet while working in a lab.

Image source: Getty Images

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

The S&P/ASX 200 Index (ASX: XJO) is up a very healthy 0.8% today, but this ASX 200  healthcare share is leaving those gains wanting.

Shares in the biopharmaceutical company closed on Wednesday trading for $20.71.

The stock then entered a trading halt pending an announcement on the results of its phase 2 clinical trial for one of its drug candidates intended to treat patients with Pitt Hopkins syndrome.

The ASX 200 healthcare share exited that trading halt this morning following on that announcement, which saw shares leap to $23.07 apiece, up 11.4%.

After some likely profit-taking, shares are currently changing hands for $22.67 apiece, up 9.5%.

Any guesses?

If you said Neuren Pharmaceuticals Ltd (ASX: NEU), go to the front of the virtual class.

Here's what's spurring investor interest on Monday.

ASX 200 healthcare share soars on significant results improvements

The Neuren Pharmaceuticals share price is leaping higher today after the company reported on the top-line results from its phase 2 clinical trial of NNZ-2591 in children with Pitt Hopkins syndrome (PTHS).

PTHS can be severely debilitating for patients, yet there are currently no approved treatments for the disease.

And investors are bidding up the ASX 200 healthcare share after Neuren Pharmaceuticals noted a "statistically significant improvement" was observed relative to the baseline following treatment. That improvement was observed by both caregivers and clinicians across all four efficacy measures designed to assess the core characteristics of PTHS.

Patients showed improvements in areas including communication, social interaction, cognition and motor abilities.

Nine out of 11 children assessed by clinicians showed improvement, while eight out of 11 children assessed by caregivers showed improvement.

NNZ-2591 was also reported to be safe and well tolerated, with no serious or severe adverse events during the phase 2 trial.

Commenting on the clinical trial results sending the ASX 200 healthcare share soaring today, Neuren Pharmaceuticals CEO Jon Pilcher said:

We are very excited about the results of this first clinical trial in Pitt Hopkins patients. This underserved community has such urgent unmet need, and we can now continue towards our goal of developing a first approved treatment.

We are very grateful to the people in the Pitt Hopkins community and at the trial sites in the United States who enabled the successful completion of this extremely challenging, but groundbreaking trial.

Nancy Jones, Neuren vice president of Clinical Development added:

The consistent results on the PTHS specific assessments affirm the need for syndrome specific measurements in severe neurodevelopmental disorders where measures that were developed for broader populations may not be as appropriate.

Neuren Pharmaceuticals share price snapshot

With today's intraday gains factored in, the ASX 200 healthcare share is up an impressive 67% since this time last year.

Motley Fool contributor Bernd Struben has no position in any of the stocks mentioned. The Motley Fool Australia's parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Scott Phillips.

More on Share Gainers

A woman with strawberry blonde hair has a huge smile on her face and fist pumps the air having seen good news on her phone.
Share Gainers

Why Evolution Mining, Macquarie, Ramsay, and SGH shares are pushing higher today

These shares are having a good session on Tuesday. Let's see what is getting investors excited.

Read more »

A young man talks tech on his phone while looking at a laptop. A financial graph is superimposed across the image.
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough start to the trading week this Monday.

Read more »

A steel worker peers out from under his protective headwear which is tipped back on his head as he stares solemnly straight ahead with steel production equipment in the background.
Share Gainers

Why is everyone talking about BlueScope Steel shares on Monday?

It seems Trump's tariffs have winners as well as losers...

Read more »

Two lab workers fist pump each other.
Healthcare Shares

Guess which ASX 300 healthcare stock just rocketed 20% on BIG earnings growth

Investors are piling into the ASX 300 healthcare stock on Monday. But why?

Read more »

a young woman raises her hands in joyful celebration as she sits at her computer in a home environment.
Share Gainers

Why Ansell, GQG, Mayne Pharma, and Star shares are charging higher today

These shares are starting the week on a positive note. But why?

Read more »

People sit in rollercoaster seats with expressions of fear, terror and exhilaration as it goes into a steep downward descent representing the Novonix share price in FY22
Share Gainers

Here are the top 10 ASX 200 shares today

ASX investors had a rough end to the trading week this Friday.

Read more »

Siblings jumping on a trampoline.
Share Gainers

These 3 ASX 200 stocks are charging higher this week. Own any?

Investors have been piling into these ASX 200 stocks this week. But why?

Read more »

A young woman holding her phone smiles broadly and looks excited, after receiving good news.
Share Gainers

Why Domino's, Nick Scali, REA, and Sigma shares are charging higher today

These shares are ending the week on a high. Let's see why investors are bidding them higher today.

Read more »